Kallikrein protects against microalbuminuria in experimental type i diabetes

Kidney International

Volumn 76, Issue 4, 2009, Pages 395-403

  Bodin, Sophie ^a,b,c   Chollet, Catherine ^a,b,c   Goncalves Mendes, Nicolas ^a,b,c   Gardes, Joelle ^a,b,c   Pean, Franck ^b,d   Heudes, Didier ^a,b,c   Bruneval, Patrick ^a,b,c   Marre, Michel ^b,d   Alhenc Gelas, François ^a,b,c   Bouby, Nadine ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSERM   (France)

Author keywords

Diabetic nephropathy; Kallikrein kinin system; Microalbuminuria; Renin angiotensin system; Tissue kallikrein

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; EZRIN; KALLIKREIN; KIDNEY INJURY MOLECULE 1; KININ; KININOGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; KALLIKREIN KININ SYSTEM; MICROALBUMINURIA; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STREPTOZOCIN DIABETES; TISSUE LEVEL; TUBULAR DYSFUNCTION;

ALBUMINURIA; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; KIDNEY; MICE; MICE, KNOCKOUT; STREPTOZOCIN; TISSUE KALLIKREINS;

EID: 68249129012     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.208     Document Type: Article

References (52)

1. Seaquist ER, Goetz FC, Rich S et al. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320: 1161-1165.
2. Borch-Johnsen K, Norgaard K, Hommel E et al. Is diabetic nephropathy an inherited complication? Kidney Int 1992; 41: 719-722.
3. Cambien F, Alhenc-Gelas F, Herbeth B et al. Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study. Am J Hum Genet 1988; 43: 774-780.
4. Costerousse O, Allegrini J, Lopez M et al. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J 1993; 290 (Part 1): 33-40.
5. Rigat B, Hubert C, Alhenc-Gelas F et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
6. Marre M, Bernadet P, Gallois Y et al. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 1994; 43: 384-388.
7. Doria A, Warram JH, Krolewski AS. Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I - converting enzyme gene. Diabetes 1994; 43: 690-695.
8. Marre M, Jeunemaitre X, Gallois Y et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J Clin Invest 1997; 99: 1585-1595.
9. Boright AP, Paterson AD, Mirea L et al. Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes 2005; 54: 1238-1244.
10. Hadjadj S, Tarnow L, Forsblom C et al. Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations. J Am Soc Nephrol 2007; 18: 1284-1291.
11. Costacou T, Ellis D, Fried L et al. Sequence of progression of albuminuria and decreased GFR in persons with type 1 diabetes: a cohort study. Am J Kidney Dis 2007; 50: 721-732.
12. Huang W, Gallois Y, Bouby N et al. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci USA 2001; 98: 13330-13334.
13. Murphey LJ, Gainer JV, Vaughan DE et al. Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation 2000; 102: 829-832.
14. Takahashi N, Hagaman JR, Kim HS et al. Minireview: computer simulations of blood pressure regulation by the renin-angiotensin system. Endocrinology 2003; 144: 2184-2190.
15. Christopher J, Jaffa AA. Diabetes modulates the expression of glomerular kinin receptors. Int Immunopharmacol 2002; 2: 1771-1779.
16. Mage M, Pecher C, Neau E et al. Induction of B1 receptors in streptozotocin diabetic rats: possible involvement in the control of hyperglycemia-induced glomerular Erk 1 and 2 phosphorylation. Can J Physiol Pharmacol 2002; 80: 328-333.
17. Abdouh M, Khanjari A, Abdelazziz N et al. Early upregulation of kinin B1 receptors in retinal microvessels of the streptozotocin-diabetic rat. Br J Pharmacol 2003; 140: 33-40.
18. Kakoki M, Takahashi N, Jennette JC et al. Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci USA 2004; 101: 13302-13305.
19. Jaffa AA, Rust PF, Mayfield RK. Kinin, a mediator of diabetes-induced glomerular hyperfiltration. Diabetes 1995; 44: 156-160.
20. Zuccollo A, Navarro M, Catanzaro O. Effects of B1 and B2 kinin receptor antagonists in diabetic mice. Can J Physiol Pharmacol 1996; 74: 586-589.
21. Allard J, Buleon M, Cellier E et al. ACE inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular receptor activation in diabetic rats. Am J Physiol Renal Physiol 2007; 293: F1083-F1092.
22. Tan Y, Keum JS, Wang B et al. Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy. Am J Physiol Renal Physiol 2007; 293: F1026-F1035.
23. Lawson SR, Gabra BH, Nantel F et al. Effects of a selective bradykinin B1 receptor antagonist on increased plasma extravasation in streptozotocin-induced diabetic rats: distinct vasculopathic profile of major key organs. Eur J Pharmacol 2005; 514: 69-78.
24. Duka I, Shenouda S, Johns C et al. Role of the B(2) receptor of bradykinin in insulin sensitivity. Hypertension 2001; 38: 1355-1360.
25. Griol-Charhbili V, Messadi-Laribi E, Bascands JL et al. Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB J 2005; 19: 1172-1174.
26. Meneton P, Bloch-Faure M, Hagege AA et al. Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci USA 2001; 98: 2634-2639.
27. Trabold F, Pons S, Hagege AA et al. Cardiovascular phenotypes of kinin B2 receptor- and tissue kallikrein-deficient mice. Hypertension 2002; 40: 90-95.
28. Qi Z, Fujita H, Jin J et al. Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 2005; 54: 2628-2637.
29. Kelly DJ, Aaltonen P, Cox AJ et al. Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies. Nephrol Dial Transplant 2002; 17: 1327-1332.
30. McRobert EA, Gallicchio M, Jerums G et al. The amino-terminal domains of the ezrin, radixin, and moesin (ERM) proteins bind advanced glycation end products, an interaction that may play a role in the development of diabetic complications. J Biol Chem 2003; 278: 25783-25789.
31. Hugo C, Nangaku M, Shankland SJ et al. The plasma membrane-actin linking protein, ezrin, is a glomerular epithelial cell marker in glomerulogenesis, in the adult kidney and in glomerular injury. Kidney Int 1998; 54: 1934-1944.
32. Kim JJ, Li JJ, Jung DS et al. Differential expression of nephrin according to glomerular size in early diabetic kidney disease. J Am Soc Nephrol 2007; 18: 2303-2310.
33. Bonventre JV. Kidney Injury Molecule-1 (KIM-1): a specific and sensitive biomarker of kidney injury. Scand J Clin Lab Invest Suppl 2008; 241: 78-83.
34. van Timmeren MM, Bakker SJ, Vaidya VS et al. Tubular kidney injury molecule-1 in protein-overload nephropathy. Am J Physiol Renal Physiol 2006; 291: F456-F464.
35. Waanders F, Vaidya VS, van Goor H et al. Effect of renin-angiotensinaldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. Am J Kidney Dis 2009; 53: 16-25.
36. Rodriguez AI, Pereira-Flores K, Hernandez-Salinas R et al. High glucose increases B1-kinin receptor expression and signaling in endothelial cells. Biochem Biophys Res Commun 2006; 345: 652-659.
37. Christopher J, Velarde V, Zhang D et al. Regulation of B(2)-kinin receptors by glucose in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2001; 280: H1537-H1546.
38. Picard N, Van Abel M, Campone C et al. Tissue kallikrein-deficient mice display a defect in renal tubular calcium absorption. J Am Soc Nephrol 2005; 16: 3602-3610.
39. Biyashev D, Tan F, Chen Z et al. Kallikrein activates bradykinin B2 receptors in absence of kininogen. Am J Physiol Heart Circ Physiol 2006; 290: H1244-H1250.
40. Kim HS, Krege JH, Kluckman KD et al. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 1995; 92: 2735-2739.
41. Cheng HF, Burns KD, Harris RC. Reduced proximal tubule angiotensin II receptor expression in streptozotocin-induced diabetes mellitus. Kidney Int 1994; 46: 1603-1610.
42. Alhenc-Gelas F, Baussant T, Hubert C et al. The angiotensin converting enzyme in the kidney. J Hypertens Suppl 1989; 7: S9-S13; discussion S14.
43. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265: F477-F486.
44. Wysocki J, Ye M, Soler MJ et al. ACE and ACE2 activity in diabetic mice. Diabetes 2006; 55: 2132-2139.
45. Metzger R, Bohle RM, Pauls K et al. Angiotensin-converting enzyme in non-neoplastic kidney diseases. Kidney Int 1999; 56: 1442-1454.
46. Bergaya S, Hilgers RH, Meneton P et al. Flow-dependent dilation mediated by endogenous kinins requires angiotensin AT2 receptors. Circ Res 2004; 94: 1623-1629.
47. Siragy HM, Xue C, Abadir P et al. Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation. Hypertension 2005; 45: 133-137.
48. Messadi-Laribi E, Griol-Charhbili V, Pizard A et al. Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia. J Pharmacol Exp Ther 2007; 323: 210-216.
49. Haseyama T, Fujita T, Hirasawa F et al. Complications of IgA nephropathy in a non-insulin-dependent diabetes model, the Akita mouse. Tohoku J Exp Med 2002; 198: 233-244.
50. Slim R, Torremocha F, Moreau T et al. Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity. JAm Soc Nephrol 2002; 13: 968-976.
51. Baudrie V, Laude D, Elghozi JL. Optimal frequency ranges for extracting information on cardiovascular autonomic control from the blood pressure and pulse interval spectrograms in mice. Am J Physiol Regul Integr Comp Physiol 2007; 292: R904-R912.
52. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(Delta Delta C(T)) method. Methods 2001; 25: 402-408.